But it is more than that, Ive discussed the cardiovascular and renal benefits of tirzepatide when the SURPASS-CVOT data was published (GIP: SURPASSing all expectations) But now we have trials for asthma, depression, bipolar, schizophrenia, substance use disorders, peripheral arterial disease, back pain, osteoarthritis and even more autoimmune diseases
You will
For those with hypermobility and EDS specifically, Id flag the following as the minimum due diligence before starting these medications: A thorough GI history and ideally gastric emptying assessment if theres any existing dysmotility Baseline muscle mass measurement (DEXA or similar) given the sarcopenia risk A clear plan for high-protein diet and resistance-based exercise to mitigate muscle loss Baseline bone density if theres any existing concern Consideration of the nutritional picture specific to hypermobility, since these drugs can affect appetite and nutrient absorption A conversation specifically about MCAS if thats a feature of your presentation The medication options for hypermobility and EDS are limited and often unsatisfying, and its entirely understandable why people are looking at something new with genuine curiosity
The other 19 lines of evidence were consistent with the involvement of the postnatal period and, in some cases, indicated that the postnatal period is the time of the greatest sensitivity to APAP induced neurodevelopmental injury
